This company has been marked as potentially delisted and may not be actively trading. Cardiff Oncology (TROV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock TROV vs. IZTC, JATT, CRTX, ZIVO, ALVR, FNCH, SRNE, SQZ, NKGN, and GNCAQShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Invizyne Technologies (IZTC), JATT Acquisition (JATT), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), AlloVir (ALVR), Finch Therapeutics Group (FNCH), Sorrento Therapeutics (SRNE), SQZ Biotechnologies (SQZ), NKGen Biotech (NKGN), and Genocea Biosciences (GNCAQ). These companies are all part of the "medical" sector. Cardiff Oncology vs. Its Competitors Invizyne Technologies JATT Acquisition Cortexyme ZIVO Bioscience AlloVir Finch Therapeutics Group Sorrento Therapeutics SQZ Biotechnologies NKGen Biotech Genocea Biosciences Cardiff Oncology (NASDAQ:TROV) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations. Does the media prefer TROV or IZTC? In the previous week, Cardiff Oncology's average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score. Company Overall Sentiment Cardiff Oncology Neutral Invizyne Technologies Neutral Do insiders & institutionals believe in TROV or IZTC? 10.0% of Cardiff Oncology shares are owned by institutional investors. 0.6% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher valuation & earnings, TROV or IZTC? Invizyne Technologies has lower revenue, but higher earnings than Cardiff Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$250K106.15-$16.41M-$2.80-0.86Invizyne TechnologiesN/AN/AN/AN/AN/A Is TROV or IZTC more profitable? Invizyne Technologies has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. Invizyne Technologies' return on equity of 0.00% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-3,688.31% -202.00% -122.92% Invizyne Technologies N/A N/A N/A SummaryCardiff Oncology and Invizyne Technologies tied by winning 3 of the 6 factors compared between the two stocks. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TROV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TROV vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.54M$352.12M$6.10B$10.55BDividend YieldN/AN/A5.73%4.78%P/E Ratio-0.80N/A63.4322.98Price / Sales106.15517.33604.86133.16Price / CashN/A22.4437.8662.13Price / Book2.563.8012.396.65Net Income-$16.41M-$133.30M$3.32B$276.79M Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TROVCardiff OncologyN/A$2.41+6.2%N/A-15.0%$26.54M$250K-0.80N/AHigh Trading VolumeIZTCInvizyne TechnologiesN/A$13.50+1.5%N/AN/A$84.40MN/A0.0029Gap UpJATTJATT AcquisitionN/A$4.17+6.1%N/A-13.9%$71.93MN/A0.003High Trading VolumeCRTXCortexymeN/A$1.95+18.2%N/A+151.0%$58.79MN/A-0.6655ZIVOZIVO Bioscience0.1222 of 5 stars$11.75-2.3%N/A-32.8%$44.85M$15.85K-2.4110ALVRAlloVirN/A$8.03+20.9%N/A-71.7%$40.50MN/A-0.40110News CoverageHigh Trading VolumeFNCHFinch Therapeutics Group0.8796 of 5 stars$12.03-0.8%N/A+0.8%$19.32MN/A-1.36190Short Interest ↓SRNESorrento Therapeutics0.9782 of 5 stars$0.00+14.3%N/A+118.8%$2.21M$60.32M0.00800Gap DownSQZSQZ BiotechnologiesN/A$0.03flatN/A+30.4%$826K$18.16M-0.011,620NKGNNKGen BiotechN/A$0.00+150.0%N/A-91.3%$22KN/A0.00N/AGap UpGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070 Related Companies and Tools Related Companies IZTC Competitors JATT Competitors CRTX Competitors ZIVO Competitors ALVR Competitors FNCH Competitors SRNE Competitors SQZ Competitors NKGN Competitors GNCAQ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TROV) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredWall St’s “AI Godfather” breaks his silenceWhats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
